Elsevier Inc.

SHERPA: Unknown

People

  1. Abu-Rustum
    Abu-Rustum
  2. Chi
    Chi
  3. Lee
    Lee
  4. Giralt
    Giralt
  5. Mulhall
    Mulhall
  6. Perales
    Perales
  7. Sonoda
    Sonoda
  8. Leitao
    Leitao
  9. Wu
    Wu
  10. Wolden
    Wolden

Groups

  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)
  7. Center for Hematologic Malignancies (1674)
  8. Hematologic Malignancies, Division of (1609)
  9. Gynecology Disease Management Team (1425)
  10. Sloan Kettering Institute Faculty (1413)
Search Within
Formats
  1. Journal Article (7387)
  2. Meeting Abstract (4694)
  3. Review (616)
  4. Book Section (538)
  5. Editorial (250)
  6. Conference Paper (138)
  7. Correspondence (92)
  8. Guidelines (82)
  9. Research Letter (29)
  10. Miscellaneous (15)
  11. Book Whole (14)
Groups
  1. Department of Medicine (4610)
  2. Surgery (3546)
  3. Survivorship Research (2658)
  4. Solid Tumor Oncology Division (2651)
  5. Radiation Oncology, Department of (2158)
  6. GSK Faculty (1937)

More Groups

People
  1. Nadeem Abu-Rustum (464)
  2. Dennis Chi (420)
  3. Nancy Lee (409)
  4. Michael Zelefsky (401)
  5. Sergio Giralt (384)
  6. John Mulhall (377)

More People

Years
  1. 2025 (240)
  2. 2024 (784)
  3. 2023 (762)
  4. 2022 (794)
  5. 2021 (723)
  6. 2020 (714)

More Years

Publications
  1. International Journal of Radiation Oncology, Biology, Physics (2610)
  2. Gynecologic Oncology (1197)
  3. Journal of Thoracic Oncology (967)
  4. Biology of Blood and Marrow Transplantation (815)
  5. European Journal of Cancer (524)
  6. Journal of Sexual Medicine (435)

More Publications

Results (13855)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Reduction in disease symptoms/impacts after daratumumab, lenalidomide, bortezomib, and dexamethasone treatment for transplant-eligible patients with newly diagnosed multiple myeloma (GRIFFIN study)
    Meeting Abstract

    Silbermann, R.; Laubach, J.; Kaufman, J.; Sborov, D.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L.; Anderson, L.; Nathwani, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Point-of-care anti-BCMA CAR T-cell therapy induces encouraging response rates in relapsed/ refractory multiple myeloma patients mostly with high-risk disease features
    Meeting Abstract

    Shkury, E.; Fried, S.; Itzhaki, O.; Shem-Tov, N.; Danylesko, I.; Yerushalmi, R.; Shouval, R.; Nevo, L.; Shapira-Frommer, R.; Nagler, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Impact of absolute lymphocyte count at pre-apheresis and pre-lymphodepletion on chimeric antigen receptor (CAR)-T therapy outcomes in relapsed refractory multiple myeloma (RRMM)
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Nath, K.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Vitamin D deficiency and clinical outcomes with chimeric antigen receptor T-cell therapy in relapsed/refractory multiple myeloma
    Meeting Abstract

    Nishimura, N.; Flynn, J.; Costa, B.; Devlin, S.; Farzana, T.; Chung, D.; Landau, H.; Lahoud, O.; Scordo, M.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Evaluating dynamic changes in the serum free light chain ratio and its effect on risk of progression in smoldering multiple myeloma
    Meeting Abstract

    Akhlaghi, T.; Nemirovsky, D.; Maclachlan, K.; Korde, N.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Patel, D.; Shah, U.; Tan, C. R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 high-risk subgroup analysis
    Meeting Abstract

    Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M.; Cavo, M.; Callander, N.; Costa, L.; Moreau, P.; Solomon, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Disparities in access and practice patterns of BCMA-directed T-cell engager (TCE) therapies in multiple myeloma: A global perspective
    Meeting Abstract

    Hassan, H.; Samur, M.; Cohen, A.; Einsele, H.; Moreau, P.; San-Miguel, J.; Kumar, S.; Mateos, M. V.; Avigan, D.; Berdeja, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Dendritic cell/myeloma fusion vaccine with lenalidomide maintenance following autologous hematopoietic cell transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion
    Meeting Abstract

    Karagkouni, D.; Cheloni, G.; Torres, D.; Chung, D.; Shah, N.; Callander, N.; Chodon, T.; Efebera, Y.; Geller, N.; Hematti, P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Ide-cel versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in the modified intention to-treat (mITT) population
    Meeting Abstract

    Manier, S.; Ailawadhi, S.; Rodríguez-Otero, P.; Arnulf, B.; Patel, K.; Solomon, S.; Baz, R.; Jagannath, S.; Raje, N.; Scheid, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Comprehensive genomic characterization of response and resistance to daratumumab based quadruplet induction in newly diagnosed multiple myeloma patients
    Meeting Abstract

    Maclachlan, K.; Tan, C. R.; Shekarkhand, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; McPherson, A.; Diamond, B.; Blaney, P.; Ziccheddu, B.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save